{
  "company": {
    "name": "Foresight Diagnostics",
    "website": "https://foresight-dx.com/",
    "record": "https://startuphistory.org/c/foresight-dx.com"
  },
  "status": null,
  "history_since": "2021-06-02T19:08:31.000Z",
  "baseline": {
    "snapshot_id": "7c85d77135f9926bc8dfaecf6288f25da56d001ea49483dd7834ae4134a9a797",
    "observed_at": "2021-06-02T19:08:31.000Z",
    "headline": "See more than ever before",
    "description": "The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
    "evidence": "https://web.archive.org/web/20210602190831/https://www.foresight-dx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:03:29.805Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2024-01-02T18:31:46.000Z",
      "variants": [
        {
          "headline": "See more than ever before",
          "subhead": "The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2021-06-02T19:08:31.000Z",
          "evidence": "https://web.archive.org/web/20210602190831/https://www.foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "See more than ever before",
          "subhead": "The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2021-07-31T12:32:26.000Z",
          "evidence": "https://web.archive.org/web/20210731123226/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "See more than ever before",
          "subhead": "The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2022-01-17T11:12:44.000Z",
          "evidence": "https://web.archive.org/web/20220117111244/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "See more than ever before",
          "subhead": "The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2023-03-21T07:34:37.000Z",
          "evidence": "https://web.archive.org/web/20230321073437/https://www.foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Seeing more than ever before",
          "subhead": "Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2023-09-04T08:43:39.000Z",
          "evidence": "https://web.archive.org/web/20230904084339/https://www.foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Seeing more than ever before",
          "subhead": "Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2024-01-02T18:31:46.000Z",
          "evidence": "https://web.archive.org/web/20240102183146/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Seeing more than ever before",
      "subhead": "Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
      "from": "2021-06-02T19:08:31.000Z",
      "to": "2024-01-02T18:31:46.000Z",
      "captures": 6,
      "evidence": "https://web.archive.org/web/20240102183146/https://foresight-dx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-06-02T19:08:31.000Z",
          "to": "2024-01-02T18:31:46.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2024-07-06T04:56:28.000Z",
      "variants": [
        {
          "headline": "See clearly. Act decisively.",
          "subhead": "Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
          "observed_at": "2024-07-06T04:56:28.000Z",
          "evidence": "https://web.archive.org/web/20240706045628/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "See clearly. Act decisively.",
      "subhead": "Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.",
      "from": "2024-07-06T04:56:28.000Z",
      "to": "2024-07-06T04:56:28.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20240706045628/https://foresight-dx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2024-07-06T04:56:28.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-06T17:03:29.805Z",
      "variants": [
        {
          "headline": "Breakthrough cancer diagnostics. Next-level clinical outcomes.",
          "subhead": "We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.",
          "observed_at": "2025-07-13T13:44:20.000Z",
          "evidence": "https://web.archive.org/web/20250713134420/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breakthrough cancer diagnostics. Next-level clinical outcomes.",
          "subhead": "We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.",
          "observed_at": "2026-01-17T04:29:40.000Z",
          "evidence": "https://web.archive.org/web/20260117042940/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breakthrough cancer diagnostics. Next-level clinical outcomes.",
          "subhead": "We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.",
          "observed_at": "2026-07-31T12:48:27.000Z",
          "evidence": "https://web.archive.org/web/20260731124827/https://foresight-dx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breakthrough cancer diagnostics. Next-level clinical outcomes.",
          "subhead": "We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.",
          "observed_at": "2026-11-06T17:03:29.805Z",
          "evidence": "https://foresight-dx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Breakthrough cancer diagnostics. Next-level clinical outcomes.",
      "subhead": "We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.",
      "from": "2025-07-13T13:44:20.000Z",
      "to": "2026-11-06T17:03:29.805Z",
      "captures": 4,
      "evidence": "https://foresight-dx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2025-07-13T13:44:20.000Z",
          "to": "2026-11-06T17:03:29.805Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-750ef25c44ce80f1f21371652e424f496a7cc4b2bb6c06584adfa6966518a472:6928593beed58b55727b830a7d2bb19795d83785e8f24bc62b2d3a23be33d68a:headline:846e06bfc5521c33",
      "before_evidence": "https://web.archive.org/web/20240102183146/https://foresight-dx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Seeing more than ever before” to “See clearly. Act decisively.”.",
      "between": {
        "from": "2024-01-02T18:31:46.000Z",
        "to": "2024-07-06T04:56:28.000Z"
      },
      "evidence": "https://web.archive.org/web/20240706045628/https://foresight-dx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-6928593beed58b55727b830a7d2bb19795d83785e8f24bc62b2d3a23be33d68a:e6634617ec5d336feb123e67067c28716926311a92684d6d7da0a3d3472c6078:headline:39fcd6709588789e",
      "before_evidence": "https://web.archive.org/web/20240706045628/https://foresight-dx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “See clearly. Act decisively.” to “Breakthrough cancer diagnostics. Next-level clinical outcomes.”.",
      "between": {
        "from": "2024-07-06T04:56:28.000Z",
        "to": "2025-07-13T13:44:20.000Z"
      },
      "evidence": "https://web.archive.org/web/20250713134420/https://foresight-dx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Foresight Diagnostics” company record, https://startuphistory.org/c/foresight-dx.com"
}